"No man can become rich without himself enriching others"
Andrew Carnegie



Sunday, April 29, 2012

4 Biotech Stocks To Acquire Now For Gains In 2013

Image representing Cell Therapeutics as depict...
Image via CrunchBase
One biotech stock that is currently on its way back up is Dendreon (DNDN). Dendreon is a growing player in the biotech industry with a 1.5 current ratio reported, although this number inspires less confidence than that of other biotech companies such as Jazz Pharmaceuticals (JAZZ), and Cell Therapeutics (CTIC), with current ratios of 4.2 and 3.1, respectively. Of course, these numbers are subject to change based on what each of the aforementioned companies have coming down the pipeline and past successes.While Dendreon's current ratio is disheartening, the company has a number of different drugs in the pipeline, as evidenced by the last report of $74 million in research and development (16% of the company's total operating expenses). One of the drugs being developed is DN24-02, a preventative drug for the recurrence of invasive urothelial carcinoma post-surgery, which is designed on the same platform as one of Dendreon's current... Continue to read.

Enhanced by Zemanta

No comments:

Post a Comment